Stefan Gaubatz

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 11

Top Topics

Transcription Factor

Breast Cancer Cells

Tyrosine Kinase

Top Venues

Molecular cancer research : MCR

Cell cycle (Georgetown, Tex.)

This page only lists publications with an associated author ORCID identifier.

Publications

Marco Gründl, Dörthe Gertzmann, Franziska Liss, Franziska Zenk, Laura Bähner, Victoria Schöffler, Clemens Schulte, Hans Michael Maric, Carsten Patrick Ade, Björn von Eyss, Stefan Gaubatz
Inhibition of the YAP-MMB interaction and targeting NEK2 as potential therapeutic strategies for YAP-driven cancers. Oncogene 43 (8) (2024)
Marco Gründl, Dörthe Gertzmann, Franziska Liss, Franziska Zenk, Laura Bähner, Victoria Schöffler, Clemens Schulte, Hans Michael Maric, Carsten Patrick Ade, Björn von Eyss, Stefan Gaubatz
Inhibition of the YAP-MMB interaction and targeting NEK2 as potential therapeutic strategies for YAP-driven cancers. Oncogene 43 (8) (2024)
Marco Gründl, Dörthe Gertzmann, Franziska Liss, Franziska Zenk, Laura Bähner, Victoria Schöffler, Clemens Schulte, Hans Michael Maric, Carsten Patrick Ade, Björn von Eyss, Stefan Gaubatz
Inhibition of the YAP-MMB interaction and targeting NEK2 as potential therapeutic strategies for YAP-driven cancers. Oncogene 43 (8) (2024)
Marco Gründl, Dörthe Gertzmann, Franziska Liss, Franziska Zenk, Laura Bähner, Victoria Schöffler, Clemens Schulte, Hans Michael Maric, Carsten Patrick Ade, Björn von Eyss, Stefan Gaubatz
Inhibition of the YAP-MMB interaction and targeting NEK2 as potential therapeutic strategies for YAP-driven cancers. Oncogene 43 (8) (2024)
Marco Gründl, Dörthe Gertzmann, Franziska Liss, Franziska Zenk, Laura Bähner, Victoria Schöffler, Clemens Schulte, Hans Michael Maric, Carsten Patrick Ade, Björn von Eyss, Stefan Gaubatz
Inhibition of the YAP-MMB interaction and targeting NEK2 as potential therapeutic strategies for YAP-driven cancers. Oncogene 43 (8) (2024)
Marco Gründl, Dörthe Gertzmann, Franziska Liss, Franziska Zenk, Laura Bähner, Victoria Schöffler, Clemens Schulte, Hans Michael Maric, Carsten Patrick Ade, Björn von Eyss, Stefan Gaubatz
Inhibition of the YAP-MMB interaction and targeting NEK2 as potential therapeutic strategies for YAP-driven cancers. Oncogene 43 (8) (2024)
Marco Gründl, Dörthe Gertzmann, Franziska Liss, Franziska Zenk, Laura Bähner, Victoria Schöffler, Clemens Schulte, Hans Michael Maric, Carsten Patrick Ade, Björn von Eyss, Stefan Gaubatz
Inhibition of the YAP-MMB interaction and targeting NEK2 as potential therapeutic strategies for YAP-driven cancers. Oncogene (2024)
Maria Camila Fetiva, Franziska Liss, Dörthe Gertzmann, Julius Thomas, Benedikt Gantert, Magdalena Vogl, Nataliia Sira, Grit Weinstock, Susanne Kneitz, Carsten P Ade, Stefan Gaubatz
Oncogenic YAP mediates changes in chromatin accessibility and activity that drive cell cycle gene expression and cell migration. Nucleic acids research (2023)
Steffen Hanselmann, Dörthe Gertzmann, Woo Jin Shin, Carsten P Ade, Stefan Gaubatz
Expression of the cytokinesis regulator PRC1 results in p53-pathway activation in A549 cells but does not directly regulate gene expression in the nucleus. Cell cycle (Georgetown, Tex.) (2022)
Marina Leone, Salvador Cazorla-Vázquez, Fulvia Ferrazzi, Janica L Wiederstein, Marco Gründl, Grit Weinstock, Silvia Vergarajauregui, Markus Eckstein, Marcus Krüger, Stefan Gaubatz, Felix B Engel
IQGAP3, a YAP Target, Is Required for Proper Cell-Cycle Progression and Genome Stability. Molecular cancer research : MCR 19 (10) (2021)
Marco Gründl, Susanne Walz, Laura Hauf, Melissa Schwab, Kerstin Marcela Werner, Susanne Spahr, Clemens Schulte, Hans Michael Maric, Carsten Patrick Ade, Stefan Gaubatz
Interaction of YAP with the Myb-MuvB (MMB) complex defines a transcriptional program to promote the proliferation of cardiomyocytes. PLoS genetics 16 (5) (2020)